Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar:146:56-73.
doi: 10.1016/j.ejca.2021.01.008. Epub 2021 Feb 12.

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Valentina Ambrosini  1 , Jolanta Kunikowska  2 , Eric Baudin  3 , Lisa Bodei  4 , Catherine Bouvier  5 , Jaume Capdevila  6 , Marta Cremonesi  7 , Wouter W de Herder  8 , Clarisse Dromain  9 , Massimo Falconi  10 , Melpomeni Fani  11 , Stefano Fanti  1 , Rodney J Hicks  12 , Levent Kabasakal  13 , Gregory Kaltsas  14 , Val Lewington  15 , Silvia Minozzi  16 , Michela Cinquini  16 , Kjell Öberg  17 , Wim J G Oyen  18 , Dermot O'Toole  19 , Marianne Pavel  20 , Philippe Ruszniewski  21 , Aldo Scarpa  22 , Jonathan Strosberg  23 , Anders Sundin  24 , David Taïeb  25 , Irene Virgolini  26 , Damian Wild  27 , Ken Herrmann  28 , James Yao  29
Affiliations
Review

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Valentina Ambrosini et al. Eur J Cancer. 2021 Mar.

Abstract

Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). European Association of Nuclear Medicine (EANM) Focus 3 performed a multidisciplinary Delphi process to deliver a balanced perspective on molecular imaging and radionuclide therapy in well-differentiated neuroendocrine tumours (NETs). NETs form in cells that interact with the nervous system or in glands that produce hormones. These cells, called neuroendocrine cells, can be found throughout the body, but NETs are most often found in the abdomen, especially in the gastrointestinal tract. These tumours may also be found in the lungs, pancreas and adrenal glands. In addition to being rare, NETs are also complex and may be difficult to diagnose. Most NETs are non-functioning; however, a minority present with symptoms related to hypersecretion of bioactive compounds. NETs often do not cause symptoms early in the disease process. When diagnosed, substantial number of patients are already found to have metastatic disease. Several societies' guidelines address Neuroendocrine neoplasms (NENs) management; however, many issues are still debated, due to both the difficulty in acquiring strong clinical evidence in a rare and heterogeneous disease and the different availability of diagnostic and therapeutic options across countries. EANM Focus 3 reached consensus on employing 68gallium-labelled somatostatin analogue ([68Ga]Ga-DOTA-SSA)-based PET/CT with diagnostic CT or magnetic resonance imaging (MRI) for unknown primary NET detection, metastatic NET, NET staging/restaging, suspected extra-adrenal pheochromocytoma/paraganglioma and suspected paraganglioma. Consensus was reached on employing 18fluorine-fluoro-2-deoxyglucose ([18F]FDG) PET/CT in neuroendocrine carcinoma, G3 NET and in G1-2 NET with mismatched lesions (CT-positive/[68Ga]Ga-DOTA-SSA-negative). Peptide receptor radionuclide therapy (PRRT) was recommended for second line treatment for gastrointestinal NET with [68Ga]Ga-DOTA-SSA uptake in all lesions, in G1/G2 NET at disease progression, and in a subset of G3 NET provided all lesions are positive at [18F]FDG and [68Ga]Ga-DOTA-SSA. PRRT rechallenge may be used for in patients with stable disease for at least 1 year after therapy completion. An international consensus is not only a prelude to a more standardised management across countries but also serves as a guide for the direction to follow when designing new research studies.

Keywords: Consensus; Molecular imaging; Neuroendocrine neoplasms; PRRT.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement VA reports personal fees from ESMIT and AAA outside the submitted work and is a member of ENETS advisory board, ESMO faculty staff for NET and the scientific board of ITANET; JK reports personal fees from Bayer, outside the submitted work; LB reports non-paid consultant for AAA-Novartis, Ipson, Clovis Oncology, and Curium, and a research grant from AAA-Novaris; JC reports grants and personal fees from Bayer, Eisai, Advanced Accelerator Applications, and Ipsen, and grants from Astrazeneca, Novartis, Pfizer, Merck, Sanofi, Amgen, and Exelixis outside the submitted work; WDH reports personal fees and grants from Ipsen, personal fees from Novartis, and personal fees and grants, from AAA; CD reports consultancy/advisor for Ipsen; MaF reports personal fees from AAA, Novartis, Ipsen, and Celgene outside the submitted work; MeF reports personal fees and research funding from Ipsen; SF reports personal fees from ANMI, Astellas, Bayer, BlueEarth Diagnostics, GE Healthcare, Jenssen, Novartis, Sofie Biosciences, non-financial support from AAA, Bayer, GE Healthcare, Curium, Tema Sinergie, Sanofi, Telix, outside the submitted work; RJH reports holding shares in Telix Pharmaceuticals on behalf of his institution and receiving research funding from Ispen and ITM; VL reports advisory board member of AAA and Ipsen; DOT reports personal fees from Novartis, IPSEN, AstraZeneca and grants from Wyeth Lederle and Ipsen outside the submitted work; MP reports personal fees from AAA, Pfizer, and Riemser and grants and personal fees from Novartis and IPSEN outside the submitted work; RS reports consultancy for AAA, Ipsen, Novartis, ITM and Keocyt and participation in the NETTER 1 and COMPETE Trials; JS reports consultant for Novartis and speaker's bureau for Ipsen and Lexicon outside the submitted work; DT reports personal fees from AAA/Novartis, IPSEN and Sanofi-Genzyme, outside the submitted work; DW reports personal fees from Ipsen and grants form Siemens Healthineers and Debiopharm International S.A; KH reports personal fees from Bayer, other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, outside the submitted work; JY reports financial activities with Advanced Accelerated Applications (AAA), Chiasma, Crinetics, Hutchison MediPharma, Ipsen, Merck, Novartis, and Tarvedin. EB, CB, SM, MiC, MC, LK, GK, KO, WO, ASc, ASu, and IV declare no competing interests.

Figures

Figure 1:
Figure 1:
Flow diagram of the modified Delphi process
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015;121(4):589–e97. 10.1002/cncr.29099. - DOI - PubMed
    1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3(10): 1335–e42. 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed
    1. Zamora V, Cabanne A, Salanova R, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis 2010;42(3):220–e5. 10.1016/j.dld.2009.07.018. - DOI - PubMed
    1. Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 2016; 103(2):153–e71. 10.1159/000443171. - DOI - PMC - PubMed
    1. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatinreceptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Canc 2010;17(1):R53–e73. 10.1677/ERC-09-0078. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

-